About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Senju Pharmaceutical Co. et al. v. Watson Laboratories, Inc. et al.
1:15-cv-05591; filed July 16, 2015 in the District Court of New Jersey

• Plaintiffs:  Senju Pharmaceutical Co., Ltd.; Bausch & Lomb Inc.; Bausch & Lomb Pharma Holdings Corp.
• Defendants:  Watson Laboratories, Inc.; Actavis, Inc.; Actavis Pharma, Inc.

Infringement of U.S. Patent Nos. 8,129,431 ("Aqueous Liquid Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid," issued March 6, 2012), 8,669,290 (same title, issued March 1, 2014), 8,754,131 (same title, issued June 17, 2014), 8,871,813 (same title, issued October 28, 2014), and 8,927,606 (same title, issued January 6, 2015) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of B&L's Prolensa® (bromfenac ophthalmic solution, used to treat postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery).  View the complaint here.

Gilead Sciences, Inc. et al. v. Sigmapharm Laboratories, LLC
2:15-cv-03950; filed July 16, 2015 in the Eastern District of Pennsylvania

• Plaintiffs:  Gilead Sciences, Inc.; Royalty Pharma Collection Trust
• Defendant:  Sigmapharm Laboratories, LLC

Infringement of U.S. Patent No. RE42,462 ("Carboxylic Acid Derivatives, Their Preparation and Use," issued June 14, 2011) following a Paragraph IV certification as part of Signmapharm's filing of an ANDA to manufacture a generic version of Gilead's Letairis® (ambrisentan, used to treat pulmonary arterial hypertension).  View the complaint here.

Celgene Corporation et al. v. Teva Pharmaceuticals USA, Inc.
1:15-cv-00589; filed July 10, 2015 in the District Court of Delaware

• Plaintiffs:  Celgene Corporation; Astellas Pharma, Inc.
• Defendant:  Teva Pharmaceuticals USA, Inc.

Infringement of U.S. Patent Nos. 7,608,280 ("Method of Producing FR901228," issued October 27, 2009) and 7,611,724 (same title, issued November 3, 2009) following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Celgene's Istodax® (romidepsin for injection, used to treatment of peripheral and cutaneous T-cell lymphoma).  View the complaint here.

Eli Lilly and Company v. Mylan Laboratories Ltd. et al.
1:15-cv-01083; filed July 10, 2015 in the Southern District of Indiana

• Plaintiff:  Eli Lilly and Company
• Defendants:  Mylan Laboratories Ltd.; Mylan Inc.; Mylan Pharmaceuticals Inc.

Infringement of U.S. Patent No. 7,772,209 ("Novel Antifolate Combination Therapies," issued August 10, 2010) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Lilly's Alimta® (pemetrexed for injection, used to treat malignant pleural mesothelioma and locally advanced or metastatic non-small cell lung cancer).  View the complaint here.

Eli Lilly and Company et al. v. Lupin Pharmaceuticals, Inc. et al.
1:15-cv-00877; filed July 9, 2015 in the Eastern District of Virginia

• Plaintiffs:  Eli Lilly and Company; Eli Lilly Exports S.A.; Acrux DDS Pty Ltd.
• Defendants:  Lupin Pharmaceuticals, Inc.; Lupin Ltd.

Infringement of U.S. Patent Nos. 8,435,944 ("Method and Composition for Transdermal Drug Delivery," issued May 7, 2013), 8,419,307 ("Spreading Implement," issued April 16, 2013), 8,177,449 (same title, issued May 15, 2012), 8,807,861 (same title, issued August 19, 2014), and 8,993,520 ("Method and Composition for Transdermal Drug Delivery," issued March 31, 2015) following a Paragraph IV certification as part of Lupin's filing of an ANDA to manufacture a generic version of Eli Lilly's Axiron® (testosterone metered transdermal solution, used to treat males for conditions associated with a deficiency or absence of endogenous testosterone).  View the complaint here.